Phase II studies of MVA expressing the tumour antigen 5T4 given with 5-FU based chemotherapies: safety, immunogenicity and clinical responses: 10.9
- Resource Type
- Academic Journal
- Source
- Immunology - Supplement. Dec 01, 2005 116 Suppl 1:34-34
- Subject
- Language
- English
- ISSN
- 0953-4954